Firuzan Fırat Ozer1, Sibel Akın2, Murat Gultekin3, Gozde Erturk Zararsız4. 1. Division of Geriatrics, Department of Internal Medicine, Erciyes School of Medicine, Erciyes University, 38090, Melikgazi, Kayseri, Turkey. firuzozer@gmail.com. 2. Division of Geriatrics, Department of Internal Medicine, Erciyes School of Medicine, Erciyes University, 38090, Melikgazi, Kayseri, Turkey. 3. Department of Neurology, Erciyes School of Medicine, Erciyes University, 38090, Melikgazi, Kayseri, Turkey. 4. Department of Biostatistics, Erciyes School of Medicine, Erciyes University, 38090, Melikgazi, Kayseri, Turkey.
Abstract
BACKGROUND/AIM: To assess sarcopenia and dynapenia and their relationship with disease severity and disabilities in PD and to state body composition in PD. METHODS: We conducted a case-control, cross-sectional study that included 70 patients with idiopathic PD and 85 controls. Sarcopenia was defined according to the European Working Group on Sarcopenia in Older People (EWGSOP) criteria. Dynapenia was detected by a handheld dynamometer. Bioimpedance analysis (BIA) was performed, and the SARC-F questionnaire was applied. Disabilities were appointed according to the Katz and Lawton indexes. RESULTS: Sarcopenia and dynapenia were more prevalent in PD than in controls (50 vs 30.6% and 31.4 vs 17.6%, respectively). Dynapenia was significantly associated with the severity of the disease and disabilities (p = 0.047, p = 0.001); however, sarcopenia was not. The skeletal muscle mass index (SMMI), fat mass index (FMI), and fat-free mass index (FFMI) did not differ between the PD and controls. FMI was lower in the advanced stages of the disease. Higher scores in the SARC-F questionnaire were significantly associated with disabilities and the severity of the disease (p < 0.001, p < 0.001). CONCLUSION: Muscle strength was closely associated with the severity of the disease and disabilities in PD, but muscle mass was not. Sarcopenia, defined by the SARC-F questionnaire, was a good predictor of disabilities in PD, while the EWGSOP criteria were not. PD patients have a favorable body composition even in advanced stages of the disease with lower FMI and protected lean mass.
BACKGROUND/AIM: To assess sarcopenia and dynapenia and their relationship with disease severity and disabilities in PD and to state body composition in PD. METHODS: We conducted a case-control, cross-sectional study that included 70 patients with idiopathic PD and 85 controls. Sarcopenia was defined according to the European Working Group on Sarcopenia in Older People (EWGSOP) criteria. Dynapenia was detected by a handheld dynamometer. Bioimpedance analysis (BIA) was performed, and the SARC-F questionnaire was applied. Disabilities were appointed according to the Katz and Lawton indexes. RESULTS:Sarcopenia and dynapenia were more prevalent in PD than in controls (50 vs 30.6% and 31.4 vs 17.6%, respectively). Dynapenia was significantly associated with the severity of the disease and disabilities (p = 0.047, p = 0.001); however, sarcopenia was not. The skeletal muscle mass index (SMMI), fat mass index (FMI), and fat-free mass index (FFMI) did not differ between the PD and controls. FMI was lower in the advanced stages of the disease. Higher scores in the SARC-F questionnaire were significantly associated with disabilities and the severity of the disease (p < 0.001, p < 0.001). CONCLUSION: Muscle strength was closely associated with the severity of the disease and disabilities in PD, but muscle mass was not. Sarcopenia, defined by the SARC-F questionnaire, was a good predictor of disabilities in PD, while the EWGSOP criteria were not. PDpatients have a favorable body composition even in advanced stages of the disease with lower FMI and protected lean mass.
Authors: Gulistan Bahat; Asli Tufan; Fatih Tufan; Cihan Kilic; Timur Selçuk Akpinar; Murat Kose; Nilgun Erten; Mehmet Akif Karan; Alfonso J Cruz-Jentoft Journal: Clin Nutr Date: 2016-02-11 Impact factor: 7.324
Authors: Alfonso J Cruz-Jentoft; Jean Pierre Baeyens; Jürgen M Bauer; Yves Boirie; Tommy Cederholm; Francesco Landi; Finbarr C Martin; Jean-Pierre Michel; Yves Rolland; Stéphane M Schneider; Eva Topinková; Maurits Vandewoude; Mauro Zamboni Journal: Age Ageing Date: 2010-04-13 Impact factor: 10.668
Authors: Ian Janssen; Richard N Baumgartner; Robert Ross; Irwin H Rosenberg; Ronenn Roubenoff Journal: Am J Epidemiol Date: 2004-02-15 Impact factor: 4.897